Inactivation of harmful tumour-associated proteolysis by nanoparticulate system

Area of Science:

• Biotechnology
• Oncology
• Nanomedicine

Background:

• Targeted drug delivery is crucial for effective cancer therapy.
• Breast tumor cells exhibit excessive proteolytic activity, promoting invasion and metastasis.
• Plasmin and cathepsin B are key proteases involved in malignant progression.

Purpose of the Study:

• To develop a targeted nanoparticle system for delivering protease inhibitors to breast tumor cells.
• To neutralize excessive proteolytic activity associated with breast cancer invasion and metastasis.
• To improve the efficacy of breast cancer therapy by combining targeted delivery with dual protease inhibition.

Main Methods:

• Utilized poly(d,l-lactide-co-glycolide) nanoparticles.
• Incorporated a cytokeratin-specific monoclonal antibody for targeted delivery to invasive breast epithelial cells.
• Loaded nanoparticles with cystatin, a protease inhibitor, to neutralize extracellular and intracellular proteases.

Main Results:

• The nanoparticle system successfully targeted invasive breast epithelial cells.
• The system prevented plasmin generation and released cystatin within endosomes/lysosomes.
• Cystatin effectively inactivated lysosomal cysteine proteases, including cathepsin B, crucial for extracellular matrix degradation.

Conclusions:

• This combined approach of nanoparticulate delivery and dual protease inhibition offers a promising strategy for enhancing breast cancer therapy.
• The system's ability to target tumor cells and inhibit key proteases may lead to improved patient outcomes compared to individual treatments.